Based in Holon, Israel with R&D facilities located in both Israel and South San Francisco, California, Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage cancer immunotherapy company, a leader in computational predictive target discovery which has focused on internally-discovered, drug targets for cancer immunotherapy.
What differentiates Compugen is its big data analysis system using proprietary algorithms to discover drug candidates including previously unknown or underappreciated immune checkpoints and Immuno oncology drug targets. It claims it can do so more accurately, faster, more efficiently and at a fraction of the costs of conventional